The neutropenia-related morbidity and mortality occurring after autologous bone marrow transplantation (ABMT) is increased by marrow purging procedures. While phase I through 111 clinical trials showed the enhancing activity of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on neutrophil recovery after ABMT with unpurged marrow, controversial results have been reported when purged marrow was used. Therefore, it was the aim of the present study t o evaluate the efficacy of rhGM-CSF administration in a group of patients (n = 15) with lymphoid malignancies transplanted in complete remission with mafosfamide-purged (n = 10) or unpurged (n = 5) marrow. Mafosfamide concentrations used for marrow purging were evaluated on an individual basis by means of a recently described technique that destroys the granulocyte-macrophage (granulocyte-macrophage colony-forming units [CFU-GM]) compartment, but spares 50% of the more primitive stroma adherent colony-forming cells (CFU-Blast). rhGM-CSF (10 pg/kg/d) was started Within 24 hours of ABMT and administered in a 4-hour infusion daily until the absolute neutrophil count (ANC) reached 500 x 106/L and then for 7 more days. Patients receiving mafosfamide-purged or unpurged marrow failed t o show any difference in terms of median number of days required to achieve an ANC 2 500 x lo6 (13 Y 14.0, P > .4) cells/L. As compared with retrospec-
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UTOLOGOUS bone marrow transplantation (ABMT)
A after high-dose cytotoxic therapy has been widely used as a treatment for acute leukemias and lymphomas.'-* Because of the theoretical possibility that the reinfused marrow may be contaminated with residual neoplastic cells responsible for relapse after ABMT,3 ex vivo marrow purging with pharmacologic and/or immunologic agents has been proposed to achieve elimination of residual malignant cells from the graft. 4 ABMT is associated with a 5% to 20% risk of fatal complications mainly related to the natural course of self-regulated hematopoietic regeneration that involves 3 to 4 weeks of pancytopenia, during which the recipient is at substantial risk of death from infections or bleeding.5 Hematopoietic recovery may be further delayed by marrow purging, which usually results in a significant destruction of committed progenitor cell compartmenk6 The toxicity of chemical purging to clonogenic cells may represent a dose-limiting factor and purging techniques based on an individual adjustment of the dose of drug used for marrow cleansing have been proposed to spare hematopoietic compartments directly or indirectly responsible for marrow Hematopoietic growth factors have now been purified to homogeneity; molecularly cloned using mammalian, bacterial, or yeast expression systems; and are available for clinical studies? Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is a glycoprotein able to control the survival, proliferation, and differentiation of myelo-monocytic cells both in vitro and in vivo.'O It also enhances the function of mature neutrophils and monocytes.ll Phase I through I11 trials showed that rhGM-CSF can be safely administered to patients undergoing ABMT. Both nonrandomized and randomized studies suggest that rhGM-CSF therapy is associated with a significant acceleration of neutrophil recovery.12-16 However, rhGM-CSF-induced marrow regeneration failed to occur when autologous marrow was purged with a combination of chemical and immunologic agents, due to the almost complete destruction of granulocyte-macrophage colonyforming units (CFU-GM)."
It was the aim of the present study to evaluate the efficacy of rhGM-CSF administration in a group of patients with rhGM-CSF IN ABMT 2413 lymphoid malignancies grafted in complete remission with unpurged or mafosfamide-purged autografts. Marrow purging was performed according to a recently described techniques based on an individual adjustment of the dose of mafosfamide used for marrow purging. This technique almost completely destroys the CFU-GM compartment, but spares the primitive adherent blast colony-forming units (CFU-Blast).8 Our data provide evidence that rhGM-CSF is still effective in accelerating neutrophil recovery provided that the primitive adherent CFU-Blast are partly spared by the purging procedure.
MATERIALS AND METHODS
Eight patients with acute lymphoblastic leukemia (ALL) and seven with non-Hodgkm's lymphoma (NHL) who were undergoing ABMT were included in this study. The main hematologic and laboratory data of the patients are shown in Table 1 . Patients (8 males, 7 females) ranged in age from 9 to 44 years (mean, 29 years). All patients with ALL were transplanted in first (n = 4) or second (n = 4) complete remission defined as less than 5% BM blasts on marrow aspirate. NHL patients were transplanted in remission defined with immunocytochemical criteria on marrow biopsy. The study protocol was approved by the ethical committees at each institution and informed consent was obtained from all patients before entry into the study. BM cell dose ranged from 0.6 to 1.4 x 108 nucleated cells/kg (mean, 0.98 x 108/kg). Eight ALL and two NHL patients received marrow purged with mafosfamide at an individually adjusted dose, whereas five NHL patients received unpurged marrow. The method of marrow purging has been described in detail elsewhere8 and was performed on an individual basis aimed at evaluating mafosfamideinduced growth inhibition of the primitive adherent CFU-Blast. Marrow was purged with the concentration of mafosfamide resulting in 50% inhibition of CFU-Blast growth (IDSO). With this technique, the value of CFU-Blast IDSO has been shown to be significantly higher (P 5 .05) than the CFU-GM ID95 value.8 After treatment, the marrow was cryopreserved at a controlled rate in 10% dimethylsulfoxide, 55% autologous plasma, and stored in the liquid phase of liquid nitrogen. Marrow collection and purging were performed immediately before ABMT.
Patients.
The BEAM regimen was administered to NHL patients and consisted of carmustine 300 mg/m2/d for 1 day, etoposide ( Data obtained from patients receiving rhGM-CSF were compared with those from retrospective control groups of comparably matched patients with ALL (n = 10) and NHL (n = 10) who underwent ABMT at our institution 1 year before the start of this study. The main hematologic and laboratory data of historical controls are shown in Table 2 . Historical controls and study patients received the same remission induction chemotherapy and conditioning regimens before ABMT. Control and study groups were comparable in terms of sex, age, disease phase at ABMT, infused cell dose, CFU-GM, and CFU-Blast (Tables 1 and  2 ). Supportive care after ABMT, especially with regards to antibiotic regimens, was comparable between control and study groups. Pentoxifylline was not administered to control or study patients.
The patients routinely received transfusions when hemoglobin values were less than 8.0 g/dL, and they received platelet transfusions when platelet counts were less than 20 x 109/L. Patients were regularly started on broad-spectrum intravenous antibiotics when the absolute neutrophil count (ANC) fell below 500 x 106/L. The patients were monitored with daily physical examinations, daily blood counts, electrolyte measurements, and biochemical tests of kidney and liver function.
rhGM-CSF, provided by ScheringPlough and Sandoz (Milan, Italy), was obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an rhGM-CSF gene.ls The final 15-Kd glycoprotein product contained less than 1 ng of endotoxin per milligram of protein as assessed by the Limulus amebocyte lysate assay. rhGM-CSF was administered at a dose of 10 kg/kg/d by a daily 4-hour infusion starting within 24 hours of completion of the autologous marrow infusion. Treatment was continued for 7 additional days after achieving a neutrophil count of 500 x 106/L.
Cryopreserved, purged, or unpurged BM cells were cultured for the quantitation of CFU-Blast and CFU-GM progenitor cells. The CFU-Blast assay was performed according to a recently described technique.*J9 Briefly, light-density nonadherent mononuclear marrow cells (MNCs; 5 x 105/mL) were added to confluent stromal layers and incubated for 2 hours to allow attachment of cells giving rise to CFU-Blast. The stromal layers were then washed and overlaid with 1 mL 0.3% agar in a-medium supplemented with 15% fetal bovine serum (FBS) and 2 x mol/L methylprednisolone. Cultures were incubated for 7 days in a humidified 5% C02 atmosphere at 37°C. Aggregates of 220 blast cells were scored as CFU-Blast. The assay for CFU-GM was performed as described elsewhere.20 Briefly, 5 x lo4 MNCs were plated in 35-mm petri dishes in 1-mL aliquots of Iscove's modified Dulbecco's medium (IMDM) containing 30% FBS, 5 x mol/L 2-mercaptoethanol, and 0.9% (wt/vol) methylcellulose. Cultures were stimulated with a mixture of human recombinant CSFs, including interleukin-3 (IL-3; 10 ng/mL), granulocyte-CSF (G-CSF 10 ng/mL), and GM-CSF (10 ng/mL). Recombinant IL-3 and G-CSF were generously provided from Behringwerke (Marburg, Germany) and Amgen Inc (Thousand Oaks, CA). rhGM-CSF was provided by Schering-Plough. Progenitor cell growth was evaluated after incubation of the dishes for 14 days at 37°C in a humidified atmosphere supplemented with 5% COz. Four dishes were set up for each individual data point per experiment.
The day of recovery to a count of 100 x lo6, 500 X lo6, and 1,000 x lo6 ANC/L, of recovery to a count of 1,000 X lo6 white blood cells (WBC)/L, and of recovery to a count of 50 x lo9 plateletdl was defined as the day when the first of two consecutive daily measurements was at or above the specific level. Data related to toxicity were evaluated during rhGM-CSF therapy and a subsequent 14-day observation period.
Statistical analysis was performed with the statistical package Statview (Brainpower Inc, Calabasas, CA) run on a Macintosh I1 (Apple Computer, Cupertino, CA) personal computer. Correlation coefficients were obtained for analysis of the effect of CFU-Blast progenitor cell dose, CFU-GM progenitor cell dose, and mafosfamide dose used for marrow purging on the time to achieve an ANC 2 lOO/kL, >500/wL, and 2 l,OOO/wL. Multiple linear regression analysis was performed to determine the relative contribution of each of these variables on ANC recovev. The Student's t-test for unpaired data was used to test for significance of changes in the comparison of data involving counts, such as the dose of progenitor cells infused per kilogram of body weight.
Data handling.
Statistical analysis.
RESULTS
The main characteristics of the patients receiving purged or unpurged autografts are summarized in Table 1 . There were no significant differences between the two groups in terms of sex, disease phase, or infused cell dose. Five of seven patients with NHL received unpurged marrow, whereas all patients with ALL and two with NHL were grafted with adjusted-dose mafosfamidepurged marrow. All patients were transplanted in remission. As shown in Table 1 , the number of CFU-GM, but not of CFU-Blast, infused per kilogram of body weight was significantly (P I .0005) different between the two groups. study patients receiving 10 pg/kg/d rhGM-CSF. Study patients receiving mafosfamide-purged or unpurged marrow and rhGM-CSF showed no difference in terms of median number of days required to achieve an ANC 2 500 X lo6 (13 v 14.0, P > .4), and a WBC 2 1,000 X lo6 (13 v 14, P > .4). Patients receiving rhGM-CSF showed earlier granulocyte recovery than the retrospective groups (Table  3) . Patients receiving grafts with mafosfamide-purged marrow who received rhGM-CSF reached an ANC of 500 x 106/L by day 13, as compared with day 24 (P I .0005) in the control group (Table 3) . Patients receiving grafts with unpurged marrow who received rhGM-CSF reached an ANC of 500 x 106/L by day 14, as compared with day 19 (P I .0005) in the control group (Table 3 ). Figure 1 shows the mean ANC plotted against the time from BMT. The kinetics of engraftment showed no substantial differences between the patients in the purged and unpurged groups. The median duration of rhGM-CSF therapy was 20 days (range, 17 to 31 days) in the purged group and 19 days (range, 16 to 21 days) in the unpurged group. Study patients required a mean of 5 U (range, 0 to 10 U) of red blood cells (RBCs) and 86 U (range, 0 to 245 U) of platelets. As compared with retrospective controls, rhGM-CSF administration did not influence the requirement of platelet and RBC transfusions (Table 3) .
Thirteen of the 15 patients had their BM cultured for determination of CFU-Blast and CFU-GM cell number (Table 1 ). The mafosfamide concentration used for marrow purging was evaluated on an individual basis by means of a technique that spares 50% of CFUBlast and reduces to less than 5% the CFU-GM content of the graft.* Patients who received a purged autograft were Cell culturestudies. infused with a mean (+-SD) 0.85 ? 0.79 x lo4 (range, 0.3 to 2.3 x lO4/kg) CFU-GM/kg body weight, as compared with 15.7 2 9.2 x lod (range, 6.9 to 27 x 104/kg) CFU-GM/kg body weight for the patients who received an unpurged autograft (P I .0005). In the 13 patients evaluated, the dose of CFU-GM progenitors infused per kilogram did not correlate (r = .031, P > .05) with the time required to reach an ANC 2 500 X lo6 cells/L (Fig 2) . The mean (2SD) number of CFU-Blast infused per kilogram of body weight in patients who received a purged marrow was 5.05 +-2.51 x 103/kg (range, 1.2 to 8.8 X 103/kg), as compared with 6,18 ? 2.66 X 1@/kg (range, 2.2 to 9.4 X 1@/ kg) for the patients who received an unpurged autograft (P 5 .375). A statistically significant correlation (r = -.658, P I .OS) was observed between the number of CFU-Blast infused and the number of days required to reach an ANC 2 500 x lo6 cells/L (Fig 3) . No correlation was found between mafosfamide dose and the number of days required to reach an ANC 2 1OO/yL (r = .43, P > .05), 2500/pL (r = .04, P > .05), or 21,0OO/pL (r = .01, P > .05) (Fig 4) . Similarly, no correlation (r = .22, P > .05) was found between mafosfamide dose and the number of days of rhGM-CSF administration. In multiple linear regression analysis, of the three variables studied (CFU-Blast infused per kilogram, CFU-GM infused per kilogram, and mafosfamide dose), only CFU-Blast infused per kilogram was significantly (P I .OS) associated with a shortened time to neutrophil recovery.
In general, therapy with rhGM-CSF was well tolerated. However, almost all study patients had minor complaints or complications attributed to rhGM-CSF infusion. These complaints included fever, edema, nausea, vomiting, diarrhea, rash, dyspnea, muscle cramps, leg pain, and headache. Although the toxicity of rhGM-CSF could not be easily distinguished from that usually related to marrow transplantation, mild to moderate reversible toxicities were noted in most patients, but rhGM-CSF infusions were not discontinued because of toxicity in any patients. No major liver or kidney dysfunction related to rhGM-CSF administration was observed.
The overall median duration of hospitalization in the patients who received rhGM-CSF was 28 days. For patients receiving unpurged marrow, the median hospitalization was shorter as compared with those receiving purged marrow (25 v 30 days, P I .1). In the control groups, the median duration of hospitalization was longer both for patients autografted with purged (38 days, P I .01) or unpurged (31 days, P 5 .l) marrow.
All study patients developed neutropenic fever and required the institution of broad-spectrum parenteral antibacterial agents. Patients had a median of 5 days (range, 1 to 12 days) of fever defined as oral temperature 238°C. One patient had a staphylococcal bacteriemia documented by two positive blood cultures. This infection occurred when her ANC was I 500/pL, and resolved with the use of parenteral antibacterial agents.
Two patients with ALL autografted in second complete remission died before day 100 after ABMT; one of relapse Toxicity and survival to day 100.
For and one of heart failure. The latter had a mild mitral regurgitation caused by rheumatic heart disease existing before the diagnosis of ALL. While in complete remission after ABMT, she developed a congestive cardiomyopathy refractory to standard therapeutic measures. Three other ALL patients and one NHL patient relapsed after day 100. . 1 . . . . 1 . . . . 1 . . . . 1 . . . . 1 . . . . 1 . . . . 1 . . . . 1 . . . . I All patients who relapsed had a recurrence of their primary disease. Overall, 60% of the patients reported herein were alive 100 days after BMT.
DISCUSSION
Data from nonrandomized as well as randomized studies suggested that rhGM-CSF was able to accelerate myeloid recovery in patients undergoing ABMT with unpurged marrow.12-16 Based on the observation that marrow purging prevents the beneficial effect of rhGM-CSF on hematopoietic engraftment, particularly when patients were engrafted with I 7.2 x 103/kg body weight of CFU-GM progenitors,17 it has been suggested that adequate numbers of myeloid progenitors must be transplanted to detect an effect of rhGM-CSF treatment. 21 We have recently described a marrow purging technique based on an individual adjustment of the dose of the cyclophosphamide derivative mafosfamide used for marrow purging.8 Such a technique determines in each patient the dose of mafosfamide required to spare 50% of CFU-Blast while destroying 2 95% CFU-GM.* The so-called adherent CFU-Blast represent a primitive class of hematopoietic progenitors capable of self-renewal and differentiati~n,".~~ and their content in the graft has been shown to correlate with engraftment.= Therefore, a nonrandomized clinical trial was started with the primary objective to determine whether rhGM-CSF might have a beneficial effect on the hematopoietic engraftment in patients autografted with adjusted-dose, mafosfamide-purged marrow.
Data derived from the present nonrandomized study show that rhGM-CSF administration shortens the median time required to reach an ANC 2 500 x lo6 cells/L by 5 to 11 days, as compared with retrospective control groups of compatible matched patients with lymphoid malignancies. The median number of days required to achieve an ANC >5OO/pL is not significantly different between the two groups of patients autografted with purged or unpurged marrow (13 v 14 days, P > .4), although the number of CFU-GM, but not that of CFU-Blast, was significantly lower in the patients grafted with purged marrow (Table 1) .
Engraftment values observed in our small group (5 NHL patients) of patients transplanted with unpurged marrow are comparable with those derived from nonrandomi~e d~~- ' 4 as well as randomized15J6 studies evaluating the efficacy of rhGM-CSF in ABMT. Engraftment values observed in patients receiving purged marrow are in contrast with that of othersI7 demonstrating that rhGM-CSF is ineffective in recipients of low numbers of CFU-GM ( 5 7.2 x 103/kg). Indeed, 6 of 10 patients receiving mafosfamide-purged marrow were injected with a number of CFU-GM ( 1 7 . 2 x 103/kg), but their hematopoietic recovery was similar to those receiving transplants with unpurged marrow.
Potential reasons for our excellent results in the group receiving mafosfamide-purged marrow could be represented by differences in the purging procedure or the status of the patients at ABMT. In the report by Blazar et all7 a combined immunologic and chemical purging was performed, whereas our patients were grafted with adjusteddose, mafosfamide-purged marrow. By definition: this technique spares 50% of a primitive class of progenitor cells, the so-called CFU-Blast, that could be irreversibly damaged by using a combined (immunologic and chemical) purging technique. In addition, our patients receiving purged marrow were grafted in first (n = 6) or second (n = 4) complete remission, whereas the majority of the patients reported by Blazar et all7 received transplants either beyond the second remission (10 of 25) or in relapse (6 of 25). Therefore, a markedly defective function of the m i c r o e n~i r o n m e n t ,~~~~~~~ as well as the in vivo persistence of leukemic c~I I s ,~,~~ could have negatively affected marrow engraftment.
rhGM-CSF has been shown to act more widely than on the CFU-GM compartment and stimulate multipotent hematopoietic stem cells known to survive mafosfamide p~r g i n g .~~,~* The multilineage activity of rhGM-CSF is supported by both clinicalz9 as well as e~p e r i m e n t a P~3~~ data, demonstrating that rhGM-CSF has a broad range of actions and is able to stimulate in vitro as well as in vivo the proliferation and differentiation of early progenitor cell compartments involved in hematopoietic reconstitution. 25 In a murine system, the number of adherent CFU-Blast has bccn shown to be essential for survival and to correlate with marrow engraftmentz4 In our study, provided that pharmacologic concentrations of rhGM-CSF are administered, a statistically significant correlation was found between the number of infused CFU-Blast progenitors and the number of days required to achieve an ANC 2 500/pL. Although the inclusion of CSFs has been shown to be unnecessary for the optimal in vitro growth of cells giving rise to CFU-Blast,22 it is well known that the glycosaminoglycan-mediated adherence of hematopoietic cells to stromal cells plays a major role in the compartmentalization of GM-CSF and in hematopoietic cell proliferation and differentia ti or^.^^,^^ Therefore, one could hypothesize that exogenous administered rhGM-CSF affects in vivo the stroma-adherent CFU-Blast by increasing their rate of commitment. 26 We did not investigate the presence of GM-CSF receptors on CFU-Blast, but our clinical data obtained in patients receiving transplants with a very low number of CFU-GM (0.85 2 0.79 x W / k g body weight) strongly support the hypothesis that CFU-Blast react to pharmacologic concentrations of rhGM-CSF by increasing their rate of commitment towards the myeloid lineage and giving rise to a CFU-GM progeny population, which in turn undergo accelerated terminal maturation resulting in a hematopoietic engraftment similar to that observed in patients receiving transplants with unpurged m a r r~w .~ This hypothesis is further supported by the observation that in our patients receiving grafts with purged marrow and receiving rhGM-CSF, both CFU-GM and BFU-E were detected earlier (day 7 after ABMT) than in historical controls who did not receive rhGM-CSF34 (our unpublished data).
No significant toxicity clearly ascribed to rhGM-CSF was found in the present study mainly because toxic effects are difficult to distinguish from those associated with marrow transplantation, but also probably because of the nonrandomized nature of this trial. Similarly, no significant effect was observed on platelet and RBC recovery, as has been recently reported by others.16 Indeed, the patients who received rhGM-CSF still experienced, in addition to 2 weeks of severe neutropenia, more than 3 weeks of thrombocytopenia and required platelets and RBCs. This implies that other strategies, such as combination cytokine therapy, must be explored in the future to shorten the period of pancytopenia after ABMT.
In conclusion, despite the very low dose of transplanted CFU-GM, rhGM-CSF administration after ABMT with adjusted-dose, mafosfamide-purged marrow positively acts on hematopoietic reconstitution, allowing for a pattern of hematopoietic recovery similar to that observed in patients receiving unpurged marrow. This effect seems to be related to the number of CFU-Blast spared by the purging technique and infused with the graft, as well as the disease phase of the patients at ABMT. Due to the effect of rhGM-CSF on neutrophil recovery, ABMT with chemically purged marrow becomes a safer procedure potentially available for a larger number of patients. However, prospective randomized trials are required to confirm this finding.
